Small nucleolar RNA (snoRNA) dysfunctions have been associated with cancer development. SNORD126 is an orphan C/D box snoRNA that is encoded within introns 5-6 of its host gene, cyclin B1-interacting protein 1 (CCNB1IP1). The cancer-associated molecular mechanisms triggered by SNORD126 are not fully understood. Here, we demonstrate that SNORD126 is highly expressed in hepatocellular carcinoma (HCC) and colorectal cancer (CRC) patient samples. SNORD126 increased Huh-7 and SW480 cell growth and tumorigenicity in nude mice. Knockdown of SNORD126 inhibited HepG2 and LS174T cell growth. We verified that SNORD126 was not processed into small RNAs with miRNA activity. Moreover, SNORD126 did not show a significant expression correlation with CCNB1IP1 in HCC samples or regulate CCNB1IP1 expression. Our gene expression profile analysis indicated that SNORD126-upregulated genes frequently mapped to the PI3K-AKT pathway. SNORD126 overexpression increased the levels of phosphorylated AKT, GSK-3β, and p70S6K and elevated fibroblast growth factor receptor 2 (FGFR2) expression. siRNA-mediated knockdown or AZD4547-mediated inactivation of FGFR2 in SNORD126-overexpressing Huh-7 cells inhibited AKT phosphorylation and suppressed cell growth. These findings indicate an oncogenic role for SNORD126 in cancer and suggest its potential as a therapeutic target.
Introduction
Small nucleolar RNAs (snoRNAs) are a class of small noncoding RNAs that accumulate in the nucleolus (Kiss, 2002) . There are two main classes of snoRNAs. The C/D box snoRNAs contain evolutionarily conserved box C (RUGAUGA) and D (CUGA) motifs that are located a few nucleotides away from the 5′ and 3′ ends, respectively. The H/ACA box snoRNAs have two large hairpin domains that are linked by a conserved H box motif (ANANNA) and a short ACA tail at the 3′ end (Kiss, 2001) .
Several recent studies have independently shown that snoRNAs are involved in human disease development. SNORD116 has been implicated in the Prader−Willi syndrome (PWS) (Sahoo et al., 2008; Cassidy et al., 2012) . SNORD115 regulates the alternative splicing of serotonin receptor 2 C, and SNORD115 deficiency causes key characteristics of the PWS phenotype (Kishore and Stamm, 2006; Bortolin-Cavaille and Cavaille, 2012) .
SNORD50A and SNORD50B are frequently deleted in human cancers. They bind to K-Ras and suppress its activity (Siprashvili et al., 2016) . SNORA42, SNORD33, SNORD66, and SNORD76 are oncogenes that are highly expressed in non-small cell lung cancer (NSCLC) patients compared with healthy individuals (Liao et al., 2010; Mei et al., 2012) . SNORD113-1 functions as a tumour suppressor in hepatocellular carcinoma (HCC) by inactivating ERK1/2 and SMAD2/3 phosphorylation in the MAPK/ERK and TGF-β pathways, respectively (Xu et al., 2014) . The growth arrest-specific 5 (GAS5) gene-derived snoRNAs are controlled by p53 and play important roles in mediating the p53 response to DNA damage in colorectal cancer (CRC) (Krell et al., 2014) . However, the exact molecular mechanisms of most snoRNAs in the progression of human malignancy are not fully understood and should be investigated further.
In vertebrates, snoRNAs mainly locate in the introns of protein-coding or non-coding genes and are transcribed by RNA polymerase II (Makarova and Kramerov, 2009) . After transcription, snoRNA-containing introns are spliced from pre-mRNA. The lariat is subsequently debranched, and exonucleases trim the intron ends to form mature snoRNAs (Holley and Topkara, 2011) . Increasing evidence suggests that snoRNAs are further processed to smaller RNA fragments, known as snoRNA-derived RNAs (sdRNAs) (Taft et al., 2009; Falaleeva and Stamm, 2013) . Those with gene-silencing functions are called sno-miRNAs (Brameier et al., 2011) . Quantitative RT-PCR (qRT-PCR) has demonstrated that four GAS5-encoded snoRNAs-SNORD44, SNORD78, SNORD74, and SNORD81-and their derivate sdRNAs are upregulated in prostate cancer samples compared with normal adjacent-tissue controls. Furthermore, SNORD78 and its sdRNAs are significantly increased in metastatic samples, and the processing pattern of SNORD78 is not restricted to prostate cancer (Martens-Uzunova et al., 2015) . Another study indicated that SNORD78 is processed to sno-miRNA, which displays miRNA activity in Jurkat and HeLa cells (Brameier et al., 2011) . Numerous sdRNAs have been identified by nextgeneration sequencing; most require further verification and functional characterizations.
SNORD126 is an orphan snoRNA that was initially discovered through a computational snoRNA search programme for mammalian genomes (Yang et al., 2006) . SNORD126 exists within the intron of its host gene, cyclin B1-interacting protein 1 (CCNB1IP1, also known as HEI10). The target and physiological function of SNORD126 is unknown. In this study, we demonstrate that SNORD126 expression was significantly higher in HCC and CRC patient tissues than in non-tumour tissues. SNORD126 overexpression promoted Huh-7 and SW480 cell growth, conferred resistance to chemotherapy, and increased tumorigenicity in nude mice. SNORD126 silencing inhibited HepG2 and LS174T cell growth. Our results showed that SNORD126 did not regulate the expression of its host gene. SNORD126 was not processed further into stable fragments, thus not exhibiting miRNA-like functions, even though it was predicted to have an miRNA-like activity (Brameier et al., 2011) . Using a gene expression microarray, we determined that SNORD126 activated the PI3K−AKT signalling pathway by upregulating the expression of fibroblast growth factor receptor 2 (FGFR2).
Results

SNORD126
, a C/D box snoRNA, is highly expressed in HCC and CRC SNORD126, a 77-bp snoRNA that is located within introns 5−6 of the CCNB1IP1 gene on chromosome 14 (Supplementary Figure S1A) , was significantly overexpressed in 30 HCC and 28 CRC patient samples ( Figure 1A −D, Supplementary Figure S1B and C). The association between SNORD126 expression and the clinicopathological features of HCC and CRC was assessed (Tables 1 and 2). We found that SNORD126 expression was not associated with age, gender, α-fetoprotein (AFP) (HCC), HBsAg (HCC), or the TNM stage (CRC) but was significantly correlated with the Barcelona clinic liver cancer staging classification (BCLC) stage in the HCC patients (P = 0.0137, Table 1 ). A Kaplan-Meier survival analysis showed that higher SNORD126 expression correlated with shorter survival (Supplementary Figure S1D and E).
The predicted secondary structure of SNORD126 was typical of C/D box snoRNAs that contain the C and D box motifs. It also contained the internal copies of the C and D boxes, termed the C' and D' boxes ( Figure 1E ). SNORD126 is evolutionarily conserved among mammalian species. However, the mouse CCNB1IP1 gene contained a 913-bp deletion that encompassed the SNORD126 locus (Supplementary Figure S1F) . Northern blot and qRT-PCR assays indicated that endogenous SNORD126 was highly expressed in the HepG2 HCC and LS174T CRC cell lines ( Figure 1F and G).
SNORD126 facilitates tumour cell growth and confers resistance to chemotherapy
To evaluate the effect of SNORD126 on human cancer cells, we used a lentivirus to overexpress SNORD126 in two cell lines with low endogenous SNORD126 expression levels, Huh-7 and SW480 (Figure 2A and B) . SNORD126 overexpression significantly increased cell growth and conferred resistance to cisplatin, etoposide, and vinblastine ( Figure 2C and D, Supplementary Figure S2A ). SNORD126-overexpressing cells exhibited increased IC 50 values (Supplementary Figure S2B) . SNORD126 overexpression also increased the proliferation of 3T3-L1 cells, mouse embryonic fibroblasts lacking the murine SNORD126 homologue (Supplementary Figure S2C and D) . However, SNORD126 overexpression did not significantly affect the migration rate of Huh-7 and SW480 cells in transwell assays (Supplementary Figure S2E) . To examine the in vivo effects of SNORD126 on cell growth, we performed subcutaneous xenograft experiment and compared the palpable tumour volumes. SNORD126 overexpression significantly promoted Huh-7 and SW480 tumour growth ( Figure 3A and B). Ki67 staining of the tumour tissues showed a significantly increased percentage of Ki67-positive cells in the SNORD126 group ( Figure 3C ). When we knocked down SNORD126 in HepG2 and LS174T cells using antisense oligonucleotides (ASOs; Figures 1E, 4A and B), cell growth was decreased ( Figure 4C , Supplementary Figure S2F ). These data demonstrate that SNORD126 elevated tumour cell growth and increased cellular resistance to cytotoxic chemotherapy.
SNORD126 is not an sno-miRNA molecule
Next, we sought to explore the mechanisms of SNORD126 function in tumour cells. Numerous human snoRNAs are processed into small RNAs (20−25 nt long) with miRNA-like functions (Ender et al., 2008) . We investigated whether SNORD126 could be processed to small RNAs with miRNA-like activity and the relevant regions by using northern blot analysis. A previous report used deep sequencing analysis demonstrated that the sequences positioned on SNORD126 at 52−75 nt (covering the D box) might be processed into sno-miRNA. The same study indicated that the C box element of the snoRNAs is frequently localized within the sequences of the sno-miRNAs (Brameier et al., 2011) . Therefore, two probes complementary to the aforementioned regions were used ( Figure 1E ). Both probes hybridized the full-length SNORD126 but did not hybridize any short bands ( Figure 5A ). We also evaluated whether SNORD126 was functionally similar to miRNAs. Complementary binding sites covering the C or D box regions of SNORD126 ( Figure 1E) were cloned into the 3′UTR of the firefly luciferase gene of the pmirGLO reporter vector. The luciferase activity was not changed when the reporter plasmids were transferred into SNORD126-overexpressing Huh-7 cells ( Figure 5B ). These data suggest that no miRNA was derived from the C or D box regions of SNORD126, and SNORD126 did not function as a miRNA precursor.
SNORD126 does not regulate the expression of its host gene
Small non-coding RNAs are critical regulators of gene expression (Bhartiya and Scaria, 2016) . CCNB1IP1 has ubiquitin ligase activity and regulates cell cycle progression through the G2/M checkpoint (Toby et al., 2003) . We speculated that SNORD126 might function by regulating its host gene. To test this hypothesis, CCNB1IP1 mRNA and protein levels were measured in SNORD126-overexpressing Huh-7 and SW480 cells and in SNORD126-knockdown HepG2 and LS174T cells. Neither up-nor downregulation of SNORD126 altered CCNB1IP1 expression ( Figure 5C and D). The qRT-PCR results were confirmed using another primer pair that was complementary to a different region of CCNB1IP1 (Supplementary Figure S3) . CCNB1IP1 mRNA expression was measured in HCC clinical specimens using qRT-PCR. CCNB1IP1 was highly expressed in the cancer specimens compared with the non-tumour specimens ( Figure 5E ). Notably, there was no significant correlation between CCNB1IP1 and SNORD126 expressions in these cancer samples ( Figure 5F ). Figure 5A and B. This secondary structure was predicted based on the minimum free energy algorithm. (F) SNORD126 expression in cell lines was determined by northern blot. The density of each SNORD126 band is normalized to β-actin, and the values shown are the fold change relative to RKO cells. (G) qRT-PCR for SNORD126 expression in cell lines. The data represent mean ± SD (n = 3).
SNORD126 activates the PI3K-AKT pathway via FGFR2 j 245
These data indicate that SNORD126 did not regulate the expression of its host gene.
SNORD126 activates the PI3K−AKT signalling pathway
The aforementioned results demonstrate that SNORD126 did not show miRNA-like functions or regulate its host gene. To identify the potential SNORD126-regulated genes, we performed a gene expression microarray analysis. From the triplicates of EGFP-or SNORD126-overexpressing Huh-7 cells, 847 significantly altered probe sets (500 annotated genes, fold change >2, P < 0.01) were identified ( Figure 6A , Supplementary Table S1 ). The mRNA levels of six representative genes (three upregulated and three downregulated) were confirmed by qRT-PCR (Supplementary Figure S4A and B) . No change to CCNB1IP1 was observed (fold change = 0.980, EGFP groups vs. SNORD126 groups), which was consistent with our observation that SNORD126 did not regulate CCNB1IP1 transcription. A Kyoto Encyclopedia of Genes and Genomes (KEGG) signalling pathway analysis revealed 8 significantly upregulated and 10 significantly downregulated pathways ( Figure 6B) . Specifically, several SNORD126-upregulated genes were mapped to the PI3K −AKT signalling pathway that is involved in various cellular processes, including cell growth and proliferation (Hirsch et al., 2014; Thorpe et al., 2015; Woods et al., 2015) . Inhibiting PI3K by expressing a dominant-negative p85 regulatory subunit of PI3K, p85 (DN), in SNORD126-overexpressing Huh-7 cells arrested cell growth ( Figure 6C ), suggesting that PI3K participated in SNORD126-mediated cell growth. We also assessed the activation of the AKT protein kinase in Huh-7 cells by immunoblotting. SNORD126 overexpression distinctly increased AKT phosphorylation on Thr308 or Ser473 at 0 min compared with EGFP-overexpression. The AKT phosphorylation status was maintained for 240 min without any changes to the total AKT protein level in SNORD126-overexpressing Huh-7 cells ( Figure 6D ). Phosphorylation of GSK-3β and p70S6K, two downstream targets of AKT, was also elevated by SNORD126 ( Figure 6D ). These results were confirmed in SW480 cells (Supplementary Figure S4C) . Moreover, the immunohistochemical stains of the tumour tissues from nude mice revealed that SNORD126 also significantly increased AKT phosphorylation on Ser473 ( Figure 6E ). Inactivation of p70S6K by the mTOR inhibitor rapamycin (RAPA) in SNORD126-overexpressing Huh-7 cells significantly decreased cell growth ( Figure 6F ). These results suggest that the PI3K−AKT signalling pathway was associated with a SNORD126-facilitated malignancy.
SNORD126 activates the PI3K−AKT pathway by upregulation of FGFR2
We next sought to explore how SNORD126 activated the PI3K−AKT pathway. The gene expression microarray results demonstrate that SNORD126 overexpression upregulated several upstream receptors of PI3K, including FGFR2 and lysophosphatidic acid receptor 1 (LPAR1), which was confirmed by qRT-PCR ( Figure 7A ). SNORD126-overexpressing Huh-7 cells were treated with an FGFR2 inhibitor AZD4547 or an LPAR1 inhibitor Ki16425. The SNORD126-induced phosphorylation of AKT was inhibited by AZD4547 but not by Ki16425 ( Figure 7B) . Furthermore, AZD4547, but not Ki16425, significantly decreased Huh-7 cell growth ( Figure 7C) . By using siRNAs against FGFR2 or LPAR1, we observed that FGFR2 downregulation suppressed AKT phosphorylation and cell growth of SNORD126-overexpressing Huh-7 cells ( Figure 7D −F, top panels). In contrast, LPAR1 silencing had no effect on AKT phosphorylation or cell growth ( Figure 7D−F, bottom panels) . In addition, the SNORD126-mediated chemo-resistance was antagonized by AZD4547 treatment in Huh-7 and SW480 cells (Supplementary Figure S4D) . These results suggest that SNORD126 activated the PI3K−AKT signalling by upregulating FGFR2. 
The chi-square test was used for analysis. The average expression level served as the cut-off point.
a
The values had statistically significant differences. The chi-square test was used for analysis. The average expression level served as the cut-off point.
Discussion
There is new and mounting evidence that the snoRNAs affect cancer by modulating gene expression and regulating numerous cellular processes (Mannoor et al., 2012; Crea et al., 2014) . Recent studies have demonstrated that aberrant snoRNA expression is associated with cancer proposing, where snoRNAs play roles as tumour suppressors or oncogenes (Tanaka et al., 2000; Dong et al., 2008 Dong et al., , 2009 Liao et al., 2010; Krell et al., 2014; Xu et al., 2014) . Investigations into the expression patterns and biological functions of the snoRNAs in cancer might further elucidate the mechanism of carcinogenesis and enable the development of potential cancer diagnostics and therapeutics. In this study, we show that SNORD126 was highly expressed in HCC and CRC clinical samples. SNORD126 facilitated tumour growth through the PI3K−AKT signalling pathway rather than functioning as an miRNA or regulating its host gene ( Figure 7G ).
Next-generation sequencing studies have revealed the existence of small RNA fragments that derive from snoRNAs and tRNAs (Ender et al., 2008; Kawaji et al., 2008; Cole et al., 2009; Lee et al., 2009; Taft et al., 2009; Burroughs et al., 2011) . For example, sno-miR-28, which is derived from SNORD28, is significantly upregulated in breast cancer and participates as an miRNA in a feed-forward loop with p53 to repress the TAF9B gene (Yu et al., 2015) . One study showed that the snoRNA ACA45 is processed to small RNAs that stably associate with Ago1 and Ago2 proteins, the central components of the RNAinduced silencing complex. The same study also showed that ACA45 processing is independent of Drosha/DGCR8 but requires Dicer (Ender et al., 2008) . SNORD126 was reported to overlap with an annotated miRNA, mir-1201, without further experimental validation (Brameier et al., 2011) . Our investigation focused on the C and D box regions according to the reported structural prediction. Interestingly, our northern blot analysis indicated that no portion of the SNORD126 was processed to small RNAs ( Figure 5A ). Furthermore, we did not observe any RNA-silencing activity in the C and D box sequences ( Figure 5B) . Ago1, Ago2, Drosha, DGCR8, and Dicer proteins did not associate with SNORD126 in our RNA immunoprecipitation−immunoblotting analysis (data not shown). Minimally, the C and D boxes of SNORD126 did not present sno-miRNA signatures.
Several studies have suggested that both host gene and snoRNAs might be important for regulating cancer biology. For example, Zfas1 is a non-protein-coding snoRNA host gene that inhibits cell proliferation and differentiation without changing levels of the hosted snoRNAs (Askarian-Amiri et al., 2011). GAS5 is another non-coding snoRNA host gene that regulates cell apoptosis and growth, and its transcripts are reduced in breast cancer cells (Mourtada-Maarabouni et al., 2009) . SNORD44, which is encoded within GAS5, shows a lower expression in breast cancer and head and neck squamous cell carcinoma and is significantly associated with their prognoses (Gee et al., 2011) . We found that both SNORD126 and CCNB1IP1 were highly expressed in the HCC samples ( Figures 1A, C , and 5E, Supplementary Figure S1B) . A previous study revealed that CCNB1IP1 is overexpressed in colon samples using in situ hybridization in a cancerous tissue microarray analysis (Confalonieri et al., 2009) . The same study also found that CCNB1IP1 is underexpressed in breast cancer and NSCLC, and the low level significantly correlated with a higher risk of recurrence (Confalonieri et al., 2009) . The dysregulated expression of CCNB1IP1 in cancer samples hinted that this protein-coding gene might play diverse roles in cancers. Therefore, we explored the relationship between SNORD126 and CCNB1IP1 to further understand their functional roles in tumour development. Our data indicated that SNORD126 expression was not synchronized with CCNB1IP1 transcription (Figure 5F ), suggesting that separate mechanisms may control their transcriptional processes. Furthermore, we found that SNORD126 did not regulate CCNB1IP1 expression at both mRNA and protein levels ( Figure 5C and D, Supplementary Figure S3 ), indicating that CCNB1IP1 may not participate in SNORD126-mediated cellular malignancy.
To improve our understanding of how SNORD126 contributes to tumorigenesis, a gene expression microarray was performed to identify potential SNORD126 targets. SNORD126 affected global gene expression, with 202 and 298 genes significantly upand downregulated (fold change > 2, P < 0.01), respectively, by SNORD126 overexpression in Huh-7 cells ( Figure 6A and Supplementary Table S1 ). This result suggested that SNORD126 might exert important roles in tumorigenesis by influencing gene transcription. A KEGG analysis revealed that several signalling pathways were deregulated as a consequence of SNORD126 overexpression ( Figure 6B) . We pursued the PI3K−AKT pathway, because it is a commonly dysregulated signalling pathway in cancer (Ke et al., 2011; Papadatos-Pastos et al., 2015; Sui et al., 2015) . AKT regulates multiple downstream proteins in the PI3K −AKT pathway, including CREB, P27, MDM2, IKK, mTOR, and GSK-3β (Rudelius et al., 2006; Rodriguez-Seoane et al., 2015) . SNORD126 overexpression increased phosphorylation of GSK-3β and p70S6K, the downstream effector of mTOR ( Figure 6D and Supplementary Figure S4C) . Inactivation of GSK-3β by phosphorylation on Ser9 mediates some of the anti-apoptotic effects of AKT (Bruel-Jungerman et al., 2009) . Activation of mTOR stimulates cell proliferation and promotes translation (Morita et al., 2015) . Both are critical nodes of the PI3K−AKT pathway that have therapeutic potential.
SNORD126 increased the expression of FGFR2 ( Figure 7A ), a tyrosine-protein kinase and cell-surface FGF receptor that plays essential roles in important processes, i.e. cell proliferation, differentiation, migration, apoptosis, and embryonic development (Zhang et al., 2015) . SNORD126 also increased a second PI3K upstream receptor, LPAR1 ( Figure 7A) . We observed that the FGFR2 and LPAR1 inhibitors behaved differently toward AKT phosphorylation, even at the basal level ( Figure 7B) . The class I PI3Ks can be subdivided into class IA and class IB PI3Ks. The class IA PI3Ks are activated by receptor tyrosine kinases (RTKs), including antigen, co-stimulatory, and cytokine receptors. The class IB PI3Ks are activated by G protein-coupled receptors (GPCRs) (Okkenhaug and Vanhaesebroeck, 2003) . FGFR2 is an RTK, and LPAR1 belongs to the GPCR family. Therefore, we speculated that the different effects might be due to a lower expression of class IB PI3Ks in Huh-7 cells.
SnoRNAs function as guide RNAs for small nucleolar ribonucleoprotein particles (snoRNP) during the post-transcriptional modification process (Yang et al., 2015) . C/D box snoRNAs contain an antisense sequence that is complementary to the targeted RNA and 2′-O-methylates the nucleotide that base pairs exactly 5 nt upstream of the D or D′ box (van Nues et al., 2011) . Using a sequence alignment analysis (Basic Local Alignment Search Tool, BLAST), we analysed the FGFR2 gene, including its 5′UTR (−647 to −1 bp), 3′UTR (2466−4007 bp), and upstream region (from −2647 to −648 bp) to cover its promoter region (−937 to −687 bp). However, we did not observe a complementary sequence (>6 nt or 3 × 6 nt spaced by 1 nt gaps) between full-length SNORD126 and the FGFR2 gene. We assumed that SNORD126 snoRNP might indirectly regulate FGFR2 expression, i.e. through a transcription factor.
Recently, more compelling evidence has shown that snoRNAs play roles in the nucleolus where they regulate gene expression at the splicing and transcript stability levels. For example, HBII-52, HBII-180 C, and SNORD27 regulate alternative splicing of the serotonin receptor 5-HT 2C R, FGFR3 pre-mRNA, and E2F7 premRNA, respectively (Kishore and Stamm, 2006; Scott et al., 2012; Falaleeva et al., 2016) . SNORD83B regulates the steadystate levels of its target mRNAs (Sharma et al., 2016) . piR30840, which is derived from SNORD63, interacts with the human IL-4 pre-mRNA to mediate its degradation (Zhong et al., 2015) . Together with these data, our study shows that snoRNAs play non-canonical roles outside of the nucleolus. Further studies are needed to demonstrate how SNORD126 influences the expression of protein-coding genes.
Cell migration was unaffected by SNORD126 overexpression (Supplementary Figure S2E) , even though several focal adhesion-associated genes were elevated ( Figure 6B ). This result was not surprising, because focal adhesions are protein complexes that contain >100 components associated with diverse functions in addition to cell migration (Burridge and Guilluy, 2016) . However, cell migration is a complex process, throughout which the composition and morphology of the focal adhesion changes (Mendoza et al., 2013) . We also noted that SNORD126 upregulated several gap junction-associated genes ( Figure 6B) . Currently, we do not fully understand the role of SNORD126 in focal adhesion (dis-)assembly and whether SNORD126 enhances or blocks gap junctions. Future studies that focus on the relationships between the focal adhesion, gap junction, and SNORD126 will likely elucidate the function of SNORD126 in tumour migration and metastasis.
We demonstrated that SNORD126 was highly expressed in 30 HCC and 28 CRC clinical samples ( Figure 1A −D, Supplementary  Figure S1B and C). SNORD126 overexpression promoted tumour cell proliferation in vitro (Figure 2 ) and accelerated xenograft growth in vivo (Figure 3) . Downregulation of SNORD126 decreased cell growth (Figure 4) . Therefore, SNORD126 might be a potential cancer therapeutic target for HCC and CRC. A validation of SNORD126 expression in a large patient population and in diverse cancer types will be necessary in future investigations. The involvement of snoRNAs in cancer and other human diseases constitutes a substantial new finding in human cell biology. A better understanding of the snoRNA functions in cancer cell proliferation, cell survival, and apoptosis will enable the development of diagnostic and monitoring methods and anticancer therapeutic strategies.
Materials and methods
Patient samples
The frozen HCC and CRC patient samples and normal tissues were anonymously obtained from the Hepatic Surgery Center at Tongji Hospital, Wuhan with the approval of the local ethics committees and the written consent of each patient. Studies involving these samples were approved and handled in accordance with the Institutional Review Board of Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (SIBCB, SIBS, CAS).
Xenograft mouse model
Four-week-old female nude mice were obtained from Shanghai Laboratory Animal Center (Shanghai, China) and maintained in an accredited animal facility according to proper institutional guidelines. Nude mice were subcutaneously inoculated in their right flanks with cells that stably expressed SNORD126 and in their left flanks with cells that stably expressed EGFP. The tumours were continuously monitored, and each tumour volume was calculated using the following formula: 4/3 × (width/2) 2 × (length/2). All animal experiments were approved by the SIBS animal care and use committee.
Gene expression microarray
The gene expression microarray analysis was performed by the GeneTech Company. RNA target preparation for microarray processing was performed using the GeneChip 3′ IVT Express Kit (Affymetrix) and hybridized to the GeneChip PrimeView TM Human Gene Expression Array (Affymetrix) for 16 h at 45°C. The data were analysed with the Robust Multichip Analysis algorithm using its default analysis settings and normalized by global scaling using Partek Genomics Suite 6.6 (Partek). The normalized data were further analysed by one-way analysis of variance (ANOVA) to screen the differentially expressed genes. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to determine pathways and processes of major biological significance and importance based on the Gene Ontology (GO) annotation function and KEGG pathway function. KEGG enrichment was performed using Fisher's exact test. The P-value indicates the significance of the pathway when correlated to the conditions. The enrichment P-value of the pathway was obtained using the EASE method, which is a modified Fisher's exact probability that penalizes (i.e. subtracts) the positive agreement count by 1, which was then corrected with adjustments to the Benjamini and Hochberg false discovery rate.
Statistics
All experiments were performed at least three times, and the data are presented as mean ± standard deviation (SD) unless otherwise noted. The data were analysed using the two-tailed unpaired Student's t-test and one-way ANOVA test (GraphPad Software). The correlation analysis was performed with the Pearson correlation test (GraphPad Software).
Additional information is available in the Supplementary Materials and methods section.
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